Dr. Ying Luo, President and CEO of GNI Group Ltd., was interviewed by Shanghai Pudong TV and Oriental Finance channels for his entrepreneurship
Dr. Ying Luo, President and CEO of GNI Group Ltd., described the development history of the company's Etuary® drug product in China and the current drug discovery platform of Cullgen Inc. (Cullgen), GNI Group Ltd.'s new U.S. subsidiary, in the interview as part of the 30 minute TV program which was broadcasted in China on June 14 and June 17. Dr. Luo described the challenging experience of being an entrepreneur during financial crisis in 2009 and before the company received the Etuary® NDA approval. He also explained the potential of Cullgen's protein degradation technology platform to generate significant numbers of new drug candidates in the future. The program also includes segments filmed inside the Cullgen and Shanghai Genomics, Inc. laboratory facilities.